Formulation, characterization, and in vitro/vivo studies of aclacinomycin A-loaded solid lipid nanoparticles

References

• Chen H, Chang X, Du D, et al. (2006). Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 110:296–306
   PubMed Web of Science ®Google Scholar
• Danhier F1, Feron O, Préat V. (2010). To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–46
   PubMed Web of Science ®Google Scholar
• Gao H, Wang JY, Shen XZ, et al. (2004). Preparation of magnetic polybutylcyanoacrylate nanospheres encapsulated with aclacinomycin A and its effect on gastric tumor. World J Gastroenterol 10:2010–13
   PubMed Web of Science ®Google Scholar
• Griaznova NS, Petiushenko RM, Belianskaia IV, et al. (1992). Incorporation of an antineoplastic drug aclarubicin into liposomes in relation to the conditions of its encapsulation. Antibiot Khimioter 37:22–5
   PubMed Web of Science ®Google Scholar
• Hancock BC, Zografi G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1–12
   PubMed Web of Science ®Google Scholar
• He J, Hou S, Lu W, et al. (2007). Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J Biomed Nanotechnol 3:195–203
   Web of Science ®Google Scholar
• Hirsjärvi S1, Passirani C, Benoit JP. (2011). Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol 8:188–96
   PubMedGoogle Scholar
• Hu H, Liu D, Zhao X, et al. (2013). Preparation, characterization, cellular uptake and evaluation in vivo of solid lipid nanoparticles loaded with cucurbitacin B. Drug Dev Ind Pharm 39:770–9
   PubMed Web of Science ®Google Scholar
• Li YC, Dong L, Jia A, et al. (2006). Preparation of solid lipid nanoparticles loaded with traditional Chinese medicine by high-pressure homogenization. South Med Univ 26:541–4
   Google Scholar
• Liu J, Hu W, Chen H, et al. (2007). Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm 328:191–5
   PubMed Web of Science ®Google Scholar
• Lu W, He LC, Wang CH, et al. (2008). The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice. Int J Biol Macromol 43:320–4
   PubMed Web of Science ®Google Scholar
• Mahajan HS, Gattani SG. (2010). Nasal administration of ondansetron using a novel microspheres delivery system Part II: ex vivo and in vivo. Pharm Dev Technol 15:653–7
   PubMed Web of Science ®Google Scholar
• Müller RH1, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 50:161–77
   PubMed Web of Science ®Google Scholar
• Nanji AA, Su GL, Laposata M, et al. (2002). Pathogenesis of alcoholic liver disease – recent advances. Alcohol Clin Exp Res 26:731–6
   PubMed Web of Science ®Google Scholar
• Nitiss JL, Pourquier P, Pommier Y. (1997). Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res 57:4564–9
   PubMed Web of Science ®Google Scholar
• Service RF. (2003). Nanomaterials show signs of toxicity. Science 300:243
   PubMed Web of Science ®Google Scholar
• Shiokawa T1, Hattori Y, Kawano K, et al. (2005). Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo. Clin Cancer Res 11:2018–25
   PubMed Web of Science ®Google Scholar
• Tadwee I, Shahi SR, Thube MW. (2011). Spray dried nasal mucoadhesive microspheres of carbamazepine: preparation and in vitro/ex vivo evaluation. Int J Sci Publ Res Pharm 2:23–32
   Google Scholar
• Torchilin VP. (2010). Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 197:3–53
   PubMedGoogle Scholar
• Tsukagoshi S, Tsuruo T, Yamori T, et al. (1980). Antitumor efficacies of aclacinomycin A by oral administration. J Pharmacobiodyn 10:532–6
   Google Scholar
• Wei G, Ni W, Chiao JW, et al. (2011). A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 4:46–58
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Müller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–72
   PubMed Web of Science ®Google Scholar